The "impressive" givosiran data presented by Alnylam at the EASL meeting both affirmed a better than expected efficacy profile and eased lingering safety concerns, according to Stifel analyst Paul Matteis, who expects investors will now confident that givosiran will be approved in porphyria without restrictions. Though "there is a real kidney signal with givosiran," the analyst said it is his opinion that it's "considerably more benign" than had been previously perceived. He maintains a Buy rating on Alnylam shares and raised his price target on the stock to $116 from $110 following the EASL meeting.